繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 新药推荐 >> 泊马度胺胶囊|Pomalyst(Pomalidomide Capsules)

泊马度胺胶囊|Pomalyst(Pomalidomide Capsules)

2014-06-04 14:53:32  作者:新特药房  来源:互联网  浏览次数:274  文字大小:【】【】【
简介:泊马度胺(pomalidomide)是美国Celgene制药公司开发的新型免疫调节剂,商品名为Pomalyst。2013年2月8日,美国食品和药品监督管理局(FDA)批准该药用于治疗复发性及难治性多发性骨髓瘤。【剂型及规格】胶囊, ...

2012年7月8日,美国FDA批准Pomalyst(pomalidomide,泊马度胺)治疗其它抗癌药治疗后病情依然进展的多发性骨髓瘤患者。
多发性骨髓瘤是一种血癌,主要影响老龄人群,自骨髓的浆细胞诱发。据美国国家癌症研究院估计,每年约有2.17万名美国人被诊断出患有多发性骨髓瘤,1.071万名死于这种疾病。
Pomalyst是一种药丸,它调节人体的免疫系统,摧毁癌细胞并抑制其生长。它适宜用于先前至少已经接受过两种治疗药物,包括来那度胺(lenalidomide)和硼替佐米(bortezomib),对治疗没有应答(未能奏效)和在最后一次治疗后60天内进展(复发和难治性)的患者。
Pomalyst是免疫调节剂一类的,继来那度胺和沙利度胺(thalidomide)之后第三个药物。多发性骨髓瘤治疗需要“度身定制”,以满足各别患者的需要,Pomalyst的获准为其它药物治疗无效的患者提供了新的选择。
2012年7月,FDA曾经批准Kyprolis(carfilzomib)治疗多发性骨髓瘤。与Kyprolis相类似,Pomalyst也是通过FDA的加速审批程序获得批准,并且获得罕用药待遇。
Pomalyst的安全性和有效性在一项有221名复发或难治性多发性骨髓瘤患者参与的临床试验中进行了评估。该试验的目的是观察经治疗后癌症完全或部分消失的患者数(客观应答率,或ORR)。患者被随机分配接受单独Pomalyst或Pomalyst加低剂量皮质类固醇地塞米松(dexamethasone)。
结果显示:接受Pomalyst单一治疗的患者7.4%达到ORR。这些患者中应答时间中位数尚未得出结论(统计时依然有应答)。Pomalyst加低剂量地塞米松治疗的患者中有29.2%显示ORR,应答持续时间中位数7.4个月。
Pomalyst的标签带有一个加框警示语,提醒患者和医护人员该药不可给孕妇使用,因为它可能会导致危及生命的严重出生缺陷,该药可能导致血液凝块。
由于Pomalyst对胎儿有风险,Pomalyst通过风险评估和消减计划(REMS)配发:按照REMS要求,医师与患者签署。尤其是没有怀孕而可能受孕的女性患者,需作妊娠测试和避孕,男性患者必须根据要求采取避孕措施。药房需按照REMS认证,该药只能处方给符合要求的患者。
常见的副作用有抵御感染的白血细胞(中性粒细胞)减少、疲劳和虚弱、红细胞计数降低(贫血)、便秘、腹泻、血小板减少下降(血小板减少症)、上呼吸道感染、背部疼痛和发烧。
Pomalyst、来那度胺和沙利度胺均由Celgene公司销售,Kyprolis由Onyx制药公司销售。
应证和用途
POMALYST是一种沙利度胺类似物适用为有多发性骨髓瘤患者曾接受至少两种既往治疗包括来那度胺[lenalidomide]和硼替佐米[bortezomib]和已证实疾病进展或末次治疗完成60天内。批准是根据反应率。尚未证明临床获益,例如改善活存或症状。


HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
POMALYST® (pomalidomide) capsules, for oral use
Initial U.S. Approval: 2013
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM
See full prescribing information for complete boxed warning
EMBRYO-FETAL TOXICITY
POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects (4, 5.1, 8.1).
For females of reproductive potential: Exclude pregnancy before start of treatment. Prevent pregnancy during treatment by the use of 2 reliable methods of contraception (5.1, 8.6).
POMALYST is available only through a restricted program called POMALYST REMS® (5.2).
VENOUS AND ARTERIAL THROMBOEMBOLISM
Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Antithrombotic prophylaxis is recommended (5.3).
RECENT MAJOR CHANGES

Boxed Warning    04/15
Indications and Usage (1.1)    04/15
Dosage and Administration (2.1, 2.2)    04/15
Warnings and Precautions (5.3, 5.4, 5.5, 5.6, 5.7, 5.8)    04/15
Warnings and Precautions (5.10)    05/14
INDICATIONS AND USAGE
POMALYST is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy (1.1).
DOSAGE AND ADMINISTRATION
4 mg per day taken orally on Days 1-21 of repeated 28-day cycles until disease progression (2.1). Refer to section 14.1 for dexamethasone dosing (14.1).
DOSAGE FORMS AND STRENGTHS
Capsules: 1 mg, 2 mg, 3 mg, and 4 mg (3)
CONTRAINDICATIONS
Pregnancy (4)
WARNINGS AND PRECAUTIONS
Hematologic Toxicity: Neutropenia was the most frequently reported Grade 3/4 adverse event. Monitor patients for hematologic toxicities, especially neutropenia (5.4).
Hepatotoxicity: Hepatic failure including fatalities; monitor liver function tests monthly (5.5).
Hypersensitivity Reactions: Angioedema and severe dermatologic reactions have been reported. Discontinue POMALYST for angioedema and severe dermatologic reactions (5.6).
Tumor Lysis Syndrome (TLS): Monitor patients at risk of TLS (i.e., those with high tumor burden) and take appropriate precautions (5.10).
ADVERSE REACTIONS
Most common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
Strong CYP1A2 Inhibitors: Avoid the use of strong CYP1A2 inhibitors unless medically necessary (2.3, 7.1, 12.3).
USE IN SPECIFIC POPULATIONS
Nursing Mothers: Discontinue drug or nursing taking into consideration importance of drug to mother (8.3).
Avoid POMALYST in patients with serum creatinine >3.0 mg/dL (8.7).
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
Revised: 4/2015
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE

1.1 Multiple Myeloma
POMALYST, in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
2 DOSAGE AND ADMINISTRATION
2.1 Multiple Myeloma
Females of reproductive potential must have negative pregnancy testing and use contraception methods before initiating POMALYST [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].
The recommended starting dose of POMALYST is 4 mg once daily orally on Days 1-21 of repeated 28-day cycles until disease progression. POMALYST should be given in combination with dexamethasone [see Clinical Studies (14.1)].
POMALYST may be taken with water. Inform patients not to break, chew, or open the capsules. POMALYST should be taken without food (at least 2 hours before or 2 hours after a meal).
2.2 Dose Adjustments for Toxicities
Table 1: Dose Modification Instructions for POMALYST for Hematologic Toxicities

Toxicity   Dose Modification
  Neutropenia
  • ANC <500 per mcL or febrile neutropenia (fever more than or equal to 38.5°C and ANC <1,000 per mcL)

  • ANC return to more than or equal to 500 per mcL

  • Interrupt POMALYST treatment, follow CBC weekly

  • Resume POMALYST treatment at 3 mg daily
  • For each subsequent drop <500 per mcL

  • Return to more than or equal to 500 per mcL
  • Interrupt POMALYST treatment

  • Resume POMALYST treatment at 1 mg less than the previous dose
  Thrombocytopenia
  • Platelets <25,000 per mcL

  • Platelets return to >50,000 per mcL

  • Interrupt POMALYST treatment, follow CBC weekly

  • Resume POMALYST treatment at 3 mg daily
  • For each subsequent drop <25,000 per mcL

  • Return to more than or equal to 50,000 per mcL
  • Interrupt POMALYST treatment

  • Resume POMALYST treatment at 1 mg less than previous dose
ANC, absolute neutrophil count
To initiate a new cycle of POMALYST, the neutrophil count must be at least 500 per mcL and the platelet count must be at least 50,000 per mcL. If toxicities occur after dose reductions to 1 mg, then discontinue POMALYST.
Permanently discontinue POMALYST for angioedema, skin exfoliation, bullae, or any other severe dermatologic reaction [see Warnings and Precautions (5.6)].
For other Grade 3 or 4 toxicities, hold treatment and restart treatment at 1 mg less than the previous dose when toxicity has resolved to less than or equal to Grade 2 at the physician’s discretion.
2.3 Dose Adjustment for Strong CYP1A2 Inhibitors in the Presence of Strong CYP3A4 and P-gp Inhibitors
Avoid co-administration of strong inhibitors of CYP1A2. If necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, reduce POMALYST dose by 50%. No clinical efficacy or safety data exist [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
3 DOSAGE FORMS AND STRENGTHS
POMALYST is available in the following capsule strengths:
1 mg: Dark blue opaque cap and yellow opaque body, imprinted “POML” on the cap in white ink and “1 mg” on the body in black ink
2 mg: Dark blue opaque cap and orange opaque body, imprinted “POML” on the cap and “2 mg” on the body in white ink
3 mg: Dark blue opaque cap and green opaque body, imprinted “POML” on the cap and “3 mg” on the body in white ink
4 mg: Dark blue opaque cap and blue opaque body, imprinted “POML” on the cap and “4 mg” on the body in white ink 
4 CONTRAINDICATIONS
PregnancyPOMALYST can cause fetal harm when administered to a pregnant female [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. POMALYST is contraindicated in females who are pregnant. Pomalidomide is a thalidomide analogue and is teratogenic in both rats and rabbits when administered during the period of organogenesis. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
5 WARNINGS AND PRECAUTIONS
5.1 Embryo-Fetal Toxicity
POMALYST is a thalidomide analogue and is contraindicated for use during pregnancy. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death [see Use in Specific Populations (8.1)]. POMALYST is only available through the POMALYST REMS program [see Warnings and Precautions (5.2)].
Females of Reproductive Potential
Females of reproductive potential must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy.
Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy.
Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing POMALYST therapy and then weekly during the first month, then monthly thereafter in women with regular menstrual cycles, or every 2 weeks in women with irregular menstrual cycles [see Use in Specific Populations (8.6)].
Males
Pomalidomide is present in the semen of patients receiving the drug. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 28 days after discontinuing POMALYST, even if they have undergone a successful vasectomy. Male patients taking POMALYST must not donate sperm [see Use in Specific Populations (8.6)].
Blood Donation
Patients must not donate blood during treatment with POMALYST and for 1 month following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to POMALYST.
5.2 POMALYST REMS Program
Because of the embryo-fetal risk [see Warnings and Precautions (5.1)], POMALYST is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called “POMALYST REMS.”
Required components of the POMALYST REMS program include the following:
Prescribers must be certified with the POMALYST REMS program by enrolling and complying with the REMS requirements.
Patients must sign a Patient-Physician Agreement Form and comply with the REMS requirements. In particular, female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements [see Use in Specific Populations (8.6)] and males must comply with contraception requirements [see Use in Specific Populations (8.6)].
Pharmacies must be certified with the POMALYST REMS program, must only dispense to patients who are authorized to receive POMALYST, and comply with REMS requirements.
Further information about the POMALYST REMS program is available at www.CelgeneRiskManagement.com or by telephone at 1-888-423-5436.
5.3 Venous and Arterial Thromboembolism
Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboembolic events (myocardial infarction and stroke) have been observed in patients treated with POMALYST. In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. Venous thromboembolic events (VTE) occurred in 4.7% of patients treated with POMALYST and Low-dose Dex, and 1.3% of patients treated with high-dose dexamethasone. Arterial thromboembolic events include terms for arterial thromboembolic events, ischemic cerebrovascular conditions, and ischemic heart disease. Arterial thromboembolic events occurred in 3.0% of patients treated with POMALYST and Low-dose Dex, and 1.3% of patients treated with high-dose dexamethasone.
Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors.
5.4 Hematologic Toxicity
In trials 1 and 2 in patients who received POMALYST + Low-dose Dex, neutropenia was the most frequently reported Grade 3/4 adverse reaction, followed by anemia and thrombocytopenia. Neutropenia of any grade was reported in 51% of patients in both trials. The rate of Grade 3/4 neutropenia was 46%. The rate of febrile neutropenia was 8%.
Monitor patients for hematologic toxicities, especially neutropenia. Monitor complete blood counts weekly for the first 8 weeks and monthly thereafter. Patients may require dose interruption and/or modification [see Dosage and Administration (2.2)].
5.5 Hepatotoxicity
Hepatic failure, including fatal cases, has occurred in patients treated with POMALYST. Elevated levels of alanine aminotransferase and bilirubin have also been observed in patients treated with POMALYST. Monitor liver function tests monthly. Stop POMALYST upon elevation of liver enzymes and evaluate. After return to baseline values, treatment at a lower dose may be considered.
5.6 Hypersensitivity Reactions
Angioedema and severe dermatologic reactions have been reported. Discontinue POMALYST for angioedema, skin exfoliation, bullae, or any other severe dermatologic reactions, and do not resume therapy [see Dosage and Administration (2.2)].
5.7 Dizziness and Confusional State
In trials 1 and 2 in patients who received POMALYST + Low-dose Dex, 14% of patients experienced dizziness and 7% of patients experienced a confusional state; 1% of patients experienced Grade 3 or 4 dizziness, and 3% of patients experienced Grade 3 or 4 confusional state. Instruct patients to avoid situations where dizziness or confusional state may be a problem and not to take other medications that may cause dizziness or confusional state without adequate medical advice.
5.8 Neuropathy
In trials 1 and 2 in patients who received POMALYST + Low-dose Dex, 18% of patients experienced neuropathy, with approximately 12% of the patients experiencing peripheral neuropathy. Two percent of patients experienced Grade 3 neuropathy in trial 2. There were no cases of Grade 4 neuropathy adverse reactions reported in either trial.
5.9 Risk of Second Primary Malignancies
Cases of acute myelogenous leukemia have been reported in patients receiving POMALYST as an investigational therapy outside of multiple myeloma.
5.10 Tumor Lysis Syndrome
Tumor lysis syndrome (TLS) may occur in patients treated with pomalidomide. Patients at risk for TLS are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken. 
6 ADVERSE REACTIONS
The following adverse reactions are described in detail in other labeling sections:
Fetal Risk [see Boxed Warnings, Warnings and Precautions (5.1, 5.2)]
Venous and Arterial Thromboembolism [see Boxed Warnings, Warnings and Precautions (5.3)]
Hematologic Toxicity [see Warnings and Precautions (5.4)]
Hepatotoxicity [see Warnings and Precautions (5.5)]
Hypersensitivity Reactions [see Warnings and Precautions (5.6)]
Dizziness and Confusional State [see Warnings and Precautions (5.7)]
Neuropathy [see Warnings and Precautions (5.8)]
Risk of Second Primary Malignancies [see Warnings and Precautions (5.9)]
Tumor Lysis Syndrome [see Warnings and Precautions (5.10)]
6.1 Clinical Trials Experience
Multiple Myeloma
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In Trial 1, data were evaluated from 219 patients (safety population) who received treatment with POMALYST + Low-dose Dex (112 patients) or POMALYST alone (107 patients). Median number of treatment cycles was 5. Sixty-seven percent of patients in the study had a dose interruption of either drug due to adverse reactions. Forty-two percent of patients in the study had a dose reduction of either drug due to adverse reactions. The discontinuation rate due to adverse reactions was 11%.
In Trial 2, data were evaluated from 450 patients (safety population) who received treatment with POMALYST + Low-dose Dex (300 patients) or High-dose Dexamethasone (High-dose Dex) (150 patients). The median number of treatment cycles for the POMALYST + Low-dose Dex arm was 5. In the POMALYST + Low-dose Dex arm, 67% of patients had a dose interruption of POMALYST, the median time to the first dose interruption of POMALYST was 4.1 weeks. Twenty-seven percent of patients had a dose reduction of POMALYST, the median time to the first dose reduction of POMALYST was 4.5 weeks. Eight percent of patients discontinued POMALYST due to adverse reactions.
Tables 2 and 3 summarize the adverse reactions reported in Trials 1 and 2, respectively.
Table 2: Adverse Reactions in Any POMALYST Treatment Arm in Trial 1* 

All Adverse Reactions ≥10% in
Either Arm
Grade 3 or 4 ≥5% in Either Arm
System Organ Class/Preferred Term
POMALYSTa
(N=107)
POMALYST +
Low-dose Dex
(N=112)

POMALYST
(N=107)
POMALYST +
Low-dose Dex
(N=112)
Number (%) of patients with at least one adverse reaction 107 (100) 112 (100) 98 (91.6) 102 (91.1)
Blood and lymphatic system disorders
     Neutropenia b 57 (53.3) 55 (49.1) 51 (47.7) 46 (41.1)
     Anemia b 41 (38.3) 47 (42.0) 25 (23.4) 24 (21.4)
     Thrombocytopenia b 28 (26.2) 26 (23.2) 24 (22.4) 21 (18.8)
     Leukopenia 14 (13.1) 22 (19.6) 7 (6.5) 11 (9.8)
     Febrile neutropenia b <10% <10% 6 (5.6) 3 (2.7)
     Lymphopenia 4 (3.7) 17 (15.2) 2 (1.9) 8 (7.1)
General disorders and administration site conditions
     Fatigue and asthenia b 62 (57.9) 70 (62.5) 13 (12.1) 19 (17.0)
     Edema peripheral 27 (25.2) 19 (17.0) 0 (0.0) 0 (0.0)
     Pyrexia b 25 (23.4) 36 (32.1) <5% <5%
     Chills 11 (10.3) 14 (12.5) 0 (0.0) 0 (0.0)
Gastrointestinal disorders
     Nausea b 39 (36.4) 27 (24.1) <5% <5%
     Constipation b 38 (35.5) 41 (36.6) <5% <5%
     Diarrhea 37 (34.6) 40 (35.7) <5% <5%
     Vomiting b 15 (14.0) 16 (14.3) <5% 0 (0.0)
Musculoskeletal and connective tissue disorders
     Back pain b 37 (34.6) 36 (32.1) 15 (14.0) 11 (9.8)
     Musculoskeletal chest pain 25 (23.4) 22 (19.6) <5% 0 (0.0)
     Muscle spasms 23 (21.5) 22 (19.6) <5% <5%
     Arthralgia 18 (16.8) 17 (15.2) <5% <5%
     Muscular weakness 15 (14.0) 15 (13.4) 6 (5.6) 4 (3.6)
     Bone pain 13 (12.1) 8 (7.1) <5% <5%
     Musculoskeletal pain 13 (12.1) 19 (17.0) <5% <5%
     Pain in extremity 8 (7.5) 16 (14.3) 0 (0.0) <5%
Infections and infestations
     Upper respiratory tract infection 40 (37.4) 32 (28.6) <5% <5%
     Pneumonia b 30 (28.0) 38 (33.9) 21 (19.6) 32 (28.6)
     Urinary tract infection b 11 (10.3) 19 (17.0) 2 (1.9) 10 (8.9)
     Sepsis b <10% <10% 6 (5.6) 5 (4.5)
Metabolism and nutrition disorders
     Decreased appetite 25 (23.4) 21 (18.8) <5% 0 (0.0)
     Hypercalcemia b 23 (21.5) 13 (11.6) 11 (10.3) 1 (0.9)
     Hypokalemia 13 (12.1) 13 (11.6) <5% <5%
     Hyperglycemia 12 (11.2) 17 (15.2) <5% <5%
     Hyponatremia 12 (11.2) 14 (12.5) <5% <5%
     Dehydration b <10% <10% 5 (4.7) 6 (5.4)
     Hypocalcemia 6 (5.6) 13 (11.6) 0 (0.0) <5%
Respiratory, thoracic and mediastinal disorders
     Dyspnea b 38 (35.5) 50 (44.6) 8 (7.5) 14 (12.5)
     Cough 18 (16.8) 25 (22.3) 0 (0.0) 0 (0.0)
     Epistaxis 18 (16.8) 12 (10.7) <5% 0 (0.0)
     Productive cough 10 (9.3) 14 (12.5) 0 (0.0) 0 (0.0)
     Oropharyngeal pain 6 (5.6) 12 (10.7) 0 (0.0) 0 (0.0)
Nervous system disorders
     Dizziness 24 (22.4) 20 (17.9) <5% <5%
     Peripheral neuropathy 23 (21.5) 20 (17.9) 0 (0.0) 0 (0.0)
     Headache 16 (15.0) 15 (13.4) 0 (0.0) <5%
     Tremor 11 (10.3) 15 (13.4) 0 (0.0) 0 (0.0)
Skin and subcutaneous tissue disorders
     Rash 22 (20.6) 18 (16.1) 0 (0.0) <5%
     Pruritus 16 (15.0) 10 (8.9) 0 (0.0) 0 (0.0)
     Dry skin 10 (9.3) 12 (10.7) 0 (0.0) 0 (0.0)
     Hyperhidrosis 8 (7.5) 18 (16.1) 0 (0.0) 0 (0.0)
     Night sweats 5 (4.7) 14 (12.5) 0 (0.0) 0 (0.0)
Investigations
     Blood creatinine increased b 20 (18.7) 11 (9.8) 6 (5.6) 3 (2.7)
     Weight decreased 16 (15.0) 10 (8.9) 0 (0.0) 0 (0.0)
     Weight increased 1 (0.9) 12 (10.7) 0 (0.0) 0 (0.0)
Psychiatric disorders
     Anxiety 14 (13.1) 8 (7.1) 0 (0.0) 0 (0.0)
     Confusional state b 13 (12.1) 15 (13.4) 6 (5.6) 3 (2.7)
     Insomnia 7 (6.5) 18 (16.1) 0 (0.0) 0 (0.0)
Renal and urinary disorders
     Renal failure b 16 (15.0) 11 (9.8) 9 (8.4) 8 (7.1)
* Regardless of attribution of relatedness to POMALYST.
a POMALYST alone arm includes all patients randomized to the POMALYST alone arm who took study drug; 61 of the 107 patients had dexamethasone added during the treatment period. 
b Serious adverse reactions were reported in at least 2 patients in any POMALYST treatment arm.
Data cutoff: 01 March 2013 
Table 3: Adverse Reactions in Trial 2

All Adverse Reactions
(≥5% in POMALYST + Low-dose
Dex arm, and at least 2% point
higher than the High-dose-Dex arm)
Grade 3 or 4
(≥1% in POMALYST + Low-dose Dex
arm, and at least 1% point higher than
the High-dose-Dex arm)
System Organ Class/Preferred Term
POMALYST +
Low-dose Dex
(N=300)
High-dose Dex
(N=150)

POMALYST +
Low-dose Dex
(N=300)
High-dose Dex
(N=150)
Number (%) of patients with at least one adverse reaction 297 (99.0) 149 (99.3) 259 (86.3) 127 (84.7)
Blood and lymphatic system disorders
     Neutropenia b 154 (51.3) 31 (20.7) 145 (48.3) 24 (16.0)
     Thrombocytopenia 89 (29.7) a 44 (29.3) a 66 (22.0) a 39 (26.0) a
     Leukopenia 38 (12.7) 8 (5.3) 27 (9.0) 5 (3.3)
     Febrile neutropenia b 28 (9.3) 0 (0.0) 28 (9.3) 0 (0.0)
General disorders and administration site conditions
     Fatigue and asthenia 140 (46.7) 64 (42.7) 26 (8.7) a 18 (12.0) a
     Pyrexia b 80 (26.7) 35 (23.3) 9 (3.0) a 7 (4.7) a
     Edema peripheral 52 (17.3) 17 (11.3) 4 (1.3) a 3 (2.0) a
     Pain 11 (3.7) a 3 (2.0) a 5 (1.7) 1 (0.7)
Infections and infestations
     Upper respiratory tract infection b 93 (31.0) 19 (12.7) 9 (3.0) 1 (0.7)
     Pneumonia b 58 (19.3) 20 (13.3) 47 (15.7) 15 (10.0)
     Neutropenic sepsis b 3 (1.0) a 0 (0.0) a 3 (1.0) 0 (0.0)
Gastrointestinal disorders
     Diarrhea 66 (22.0) 28 (18.7) 3 (1.0) a 2 (1.3) a
     Constipation 65 (21.7) 22 (14.7) 7 (2.3) 0 (0.0)
     Nausea 45 (15.0) 17 (11.3) 3 (1.0) a 2 (1.3) a
     Vomiting 23 (7.7) 6 (4.0) 3 (1.0) 0 (0.0)
Musculoskeletal and connective tissue disorders
     Back pain b 59 (19.7) 24 (16.0) 15 (5.0) 6 (4.0)
     Bone pain b 54 (18.0) 21 (14.0) 22 (7.3) 7 (4.7)
     Muscle spasms 46 (15.3) 11 (7.3) 1 (0.3) a 1 (0.7) a
     Arthralgia 26 (8.7) 7 (4.7) 2 (0.7) a 1 (0.7) a
     Pain in extremity 20 (6.7) a 9 (6.0) a 6 (2.0) 0 (0.0)
Respiratory, thoracic and mediastinal disorders
     Dyspnea b 76 (25.3) 25 (16.7) 17 (5.7) 7 (4.7)
     Cough 60 (20.0) 15 (10.0) 2 (0.7) a 1 (0.7) a
     Chronic obstructive pulmonary disease b 5 (1.7) a 0 (0.0) a 4 (1.3) 0 (0.0)
Nervous system disorders
     Peripheral neuropathy 52 (17.3) 18 (12.0) 5 (1.7) a 2 (1.3) a
     Dizziness 37 (12.3) 14 (9.3) 4 (1.3) a 2 (1.3) a
     Headache 23 (7.7) 8 (5.3) 1 (0.3) a 0 (0.0) a
     Tremor 17 (5.7) 2 (1.3) 2 (0.7) a 0 (0.0) a
     Depressed level of consciousness 5 (1.7) a 0 (0.0) a 3 (1.0) 0 (0.0)
Metabolism and nutrition disorders
     Decreased appetite 38 (12.7) 12 (8.0) 3 (1.0) a 2 (1.3) a
     Hypokalemia 28 (9.3) a 12 (8.0) a 12 (4.0) 4 (2.7)
     Hypocalcemia 12 (4.0) a 9 (6.0) a 5 (1.7) 1 (0.7)
Skin and subcutaneous tissue disorders
     Rash 23 (7.7) 2 (1.3) 3 (1.0) 0 (0.0)
     Pruritus 22 (7.3) 5 (3.3) 0 (0.0) a 0 (0.0) a
     Hyperhidrosis 15 (5.0) 1 (0.7) 0 (0.0) a 0 (0.0) a
Investigations
     Neutrophil count decreased 15 (5.0) 1 (0.7) 14 (4.7) 1 (0.7)
     Platelet count decreased 10 (3.3) a 3 (2.0) a 8 (2.7) 2 (1.3)
     White blood cell count decreased 8 (2.7) a 1 (0.7) a 8 (2.7) 0 (0.0)
     Alanine aminotransferase increased 7 (2.3) a 2 (1.3) a 5 (1.7) 0 (0.0)
     Aspartate aminotransferase increased 4 (1.3) a 2 (1.3) a 3 (1.0) 0 (0.0)
     Lymphocyte count decreased 3 (1.0) a 1 (0.7) a 3 (1.0) 0 (0.0)
Renal and urinary disorders
     Renal failure 31 (10.3) a 18 (12.0) a 19 (6.3) 8 (5.3)
Injury, poisoning and procedural complications
     Femur fracture b 5 (1.7) a 1 (0.7) a 5 (1.7) 1 (0.7)
Reproductive system and breast disorders
     Pelvic pain 6 (2.0) a 3 (2.0) a 4 (1.3) 0 (0.0)
a Percentage did not meet the criteria to be considered as an adverse reaction for POMALYST for that category of event (i.e., all adverse events or Grade 3 or 4 adverse events). 
b Serious adverse reactions were reported in at least 3 patients in the POM + Low-dose Dex arm, AND at least 1% higher than the High-dose-Dex arm percentage.
Data cutoff: 01 March 2013 
Other Adverse Reactions
Other adverse reactions of POMALYST in patients with multiple myeloma, not described above, and considered important:
Cardiac disorders: Myocardial infarction, Atrial fibrillation, Angina pectoris, Cardiac failure congestive
Ear and labyrinth disorders: Vertigo
Gastrointestinal disorders: Abdominal pain
General disorders and administration site conditions: General physical health deterioration, Non-cardiac chest pain, Multi-organ failure
Hepatobiliary disorders: Hyperbilirubinemia
Infections and infestations: Pneumocystis jiroveci pneumonia, Respiratory syncytial virus infection, Neutropenic sepsis, Bacteremia, Pneumonia respiratory syncytial viral, Cellulitis, Urosepsis, Septic shock, Clostridium difficile colitis, Pneumonia streptococcal, Lobar pneumonia, Viral infection, Lung infection
Investigations: Alanine aminotransferase increased, Hemoglobin decreased
Injury, poisoning and procedural complications: Fall, Compression fracture, Spinal compression fracture
Metabolism and nutritional disorders: Hyperkalemia, Failure to thrive
Nervous System disorders: Depressed level of consciousness, Syncope
Psychiatric disorders: Mental status change
Renal and urinary disorders: Urinary retention, Hyponatremia
Reproductive system and breast disorders: Pelvic pain
Respiratory, thoracic, and mediastinal disorders: Interstitial lung disease, Pulmonary embolism, Respiratory failure, Bronchospasm
Vascular disorders: Hypotension
6.2 Postmarketing Experience
The following adverse drug reactions have been identified from the worldwide postmarketing experience with POMALYST: Pancytopenia, tumor lysis syndrome, allergic reactions (e.g., angioedema, urticaria), elevated liver enzymes, hepatic failure (including fatal cases).
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. 
7 DRUG INTERACTIONS
Pomalidomide is primarily metabolized by CYP1A2 and CYP3A. Pomalidomide is also a substrate for P-glycoprotein (P-gp).
7.1 Drugs That May Increase Pomalidomide Plasma Concentrations
CYP1A2 inhibitors: Pomalidomide exposure is increased when POMALYST is co-administered with a strong CYP1A2 inhibitor (fluvoxamine) in the presence of a strong CYP3A4/5 and P-gp inhibitor (ketoconazole). Ketoconazole in the absence of a CYP1A2 inhibitor does not increase pomalidomide exposure. Avoid co-administration of strong CYP1A2 inhibitors (e.g. ciprofloxacin and fluvoxamine) [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)]. If it is medically necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, POMALYST dose should be reduced by 50%.
The effect of a CYP1A2 inhibitor in the absence of a co-administered CYP3A4 and P-gp inhibitor has not been studied. Monitor for toxicities if CYP1A2 inhibitors are to be co-administered in the absence of a co-administered CYP3A4 and P-gp inhibitor, and reduce dose if needed.
7.2 Drugs That May Decrease Pomalidomide Plasma Concentrations
Smoking: Cigarette smoking may reduce pomalidomide exposure due to CYP1A2 induction. Patients should be advised that smoking may reduce the efficacy of pomalidomide.
CYP1A2 inducers: Co-administration of POMALYST with drugs that are CYP1A2 inducers has not been studied and may reduce pomalidomide exposure.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category X [see Boxed Warnings and Contraindications (4)]
Risk Summary
POMALYST can cause embryo-fetal harm when administered to a pregnant female and is contraindicated during pregnancy. POMALYST is a thalidomide analogue.
Thalidomide is a human teratogen, inducing a high frequency of severe and life-threatening birth defects such as amelia (absence of limbs), phocomelia (short limbs), hypoplasticity of the bones, absence of bones, external ear abnormalities (including anotia, micropinna, small or absent external auditory canals), facial palsy, eye abnormalities (anophthalmos, microphthalmos), and congenital heart defects. Alimentary tract, urinary tract, and genital malformations have also been documented and mortality at or shortly after birth has been reported in about 40% of infants.
Pomalidomide was teratogenic in both rats and rabbits when administered during the period of organogenesis. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
If pregnancy does occur during treatment, immediately discontinue the drug. Under these conditions, refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Report any suspected fetal exposure to POMALYST to the FDA via the MedWatch program at 1-800-FDA-1088 and also to Celgene Corporation at 1-888-423-5436.
Animal Data
Pomalidomide was teratogenic in both rats and rabbits in the embryo-fetal developmental studies when administered during the period of organogenesis.
In rats, pomalidomide was administered orally to pregnant animals at doses of 25 to 1000 mg/kg/day. Malformations or absence of urinary bladder, absence of thyroid gland, and fusion and misalignment of lumbar and thoracic vertebral elements (vertebral, central, and/or neural arches) were observed at all dose levels. There was no maternal toxicity observed in this study. The lowest dose in rats resulted in an exposure (AUC) approximately 85-fold of the human exposure at the recommended dose of 4 mg/day. Other embryo-fetal toxicities included increased resorptions leading to decreased number of viable fetuses.
In rabbits, pomalidomide was administered orally to pregnant animals at doses of 10 to 250 mg/kg/day. Increased cardiac malformations such as interventricular septal defect were seen at all doses with significant increases at 250 mg/kg/day. Additional malformations observed at 250 mg/kg/day included anomalies in limbs (flexed and/or rotated fore- and/or hindlimbs, unattached or absent digit) and associated skeletal malformations (not ossified metacarpal, misaligned phalanx and metacarpal, absent digit, not ossified phalanx, and short not ossified or bent tibia), moderate dilation of the lateral ventricle in the brain, abnormal placement of the right subclavian artery, absent intermediate lobe in the lungs, low-set kidney, altered liver morphology, incompletely or not ossified pelvis, an increased average for supernumerary thoracic ribs, and a reduced average for ossified tarsals. No maternal toxicity was observed at the low dose (10 mg/kg/day) that resulted in cardiac anomalies in fetuses; this dose resulted in an exposure (AUC) approximately equal to that reported in humans at the recommended dose of 4 mg/day. Additional embryo-fetal toxicity included increased resorption.
8.3 Nursing Mothers
It is not known if pomalidomide is excreted in human milk. Pomalidomide was excreted in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from POMALYST, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
8.4 Pediatric Use
Safety and effectiveness of POMALYST in patients below the age of 18 years have not been established.
8.5 Geriatric Use
No dosage adjustment is required for POMALYST based on age.
Of the total number of patients in clinical studies of POMALYST, 44% were aged older than 65 years, while 10% were aged older than 75 years. No overall differences in effectiveness were observed between these patients and younger patients. In these studies, patients older than 65 years were more likely than patients less than or equal to 65 years of age to experience pneumonia.
8.6 Females of Reproductive Potential and Males
POMALYST can cause fetal harm when administered during pregnancy [see Use in Specific Populations (8.1)]. Females of reproductive potential must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy.
Females
Females of reproductive potential must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously: one highly effective form of contraception – tubal ligation, IUD, hormonal (birth control pills, injections, hormonal patches, vaginal rings, or implants), or partner’s vasectomy, and 1 additional effective contraceptive method – male latex or synthetic condom, diaphragm, or cervical cap. Contraception must begin 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy. Females of reproductive potential should be referred to a qualified provider of contraceptive methods, if needed.
Females of reproductive potential must have 2 negative pregnancy tests before initiating POMALYST. The first test should be performed within 10-14 days, and the second test within 24 hours prior to prescribing POMALYST. Once treatment has started and during dose interruptions, pregnancy testing for females of reproductive potential should occur weekly during the first 4 weeks of use, then pregnancy testing should be repeated every 4 weeks in females with regular menstrual cycles. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks. Pregnancy testing and counseling should be performed if a patient misses her period or if there is any abnormality in her menstrual bleeding. POMALYST treatment must be discontinued during this evaluation.
Males
Pomalidomide is present in the semen of males who take POMALYST. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 28 days after discontinuing POMALYST, even if they have undergone a successful vasectomy. Male patients taking POMALYST must not donate sperm.
8.7 Renal Impairment
Pomalidomide and its metabolites are primarily excreted by the kidneys [see Clinical Pharmacology (12.3)]. The influence of renal impairment on the safety, efficacy, and pharmacokinetics of pomalidomide has not been evaluated. Patients with serum creatinine greater than 3.0 mg/dL were excluded in clinical studies. Avoid POMALYST in patients with a serum creatinine greater than 3.0 mg/dL.
8.8 Hepatic Impairment
Pomalidomide is metabolized in the liver [see Clinical Pharmacology (12.3)]. The influence of hepatic impairment on the safety, efficacy, and pharmacokinetics of pomalidomide has not been evaluated. Patients with serum bilirubin greater than 2.0 mg/dL and AST/ALT greater than 3.0 x upper limit normal (ULN) were excluded in clinical studies. Avoid POMALYST in patients with serum bilirubin greater than 2.0 mg/dL and AST/ALT greater than 3.0 x ULN.
10 OVERDOSAGE
No specific information is available on the treatment of overdose with pomalidomide, and it is unknown whether pomalidomide or its metabolites are dialyzable.
11 DESCRIPTION
POMALYST is an immunomodulatory antineoplastic agent. The chemical name is (RS)-4-Amino-2-(2,6-dioxo-piperidin-3-yl)-isoindoline-1,3-dione and it has the following chemical structure:


The empirical formula for pomalidomide is C13H11N3O4 and the gram molecular weight is 273.24.
Pomalidomide is a yellow solid powder.  It has limited to low solubility into organic solvents and it has low solubility in all pH solutions (about 0.01 mg/mL).  Pomalidomide has a chiral carbon atom which exists as a racemic mixture of the R(+) and S(-) enantiomers.
POMALYST is available in 1-mg, 2-mg, 3-mg, and 4-mg capsules for oral administration. Each capsule contains pomalidomide as the active ingredient and the following inactive ingredients: mannitol, pregelatinized starch, and sodium stearyl fumarate. The 1-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 2, yellow iron oxide, white ink, and black ink. The 2-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 2, yellow iron oxide, FD&C red 3, and white ink. The 3-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 2, yellow iron oxide, and white ink. The 4-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 1, FD&C blue 2, and white ink.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Pomalidomide, an analogue of thalidomide, is an immunomodulatory agent with antineoplastic activity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of lenalidomide-resistant multiple myeloma cell lines and synergized with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis. Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. Pomalidomide demonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cord model.
12.2 Pharmacodynamics
The QTc prolongation potential of pomalidomide was evaluated in a single center, randomized, double-blind crossover study (N=72) using 4 mg pomalidomide, 20 mg pomalidomide, placebo, and 400 mg moxifloxacin (positive control). No significant QTc prolongation effect of pomalidomide was observed following pomalidomide doses of 4 and 20 mg.
12.3 Pharmacokinetics
Absorption
Following administration of single oral doses of POMALYST, the maximum plasma concentration (Cmax) for pomalidomide occurs at 2 and 3 hours postdose. The systemic exposure (AUC) of pomalidomide increases in an approximately dose proportional manner.
In patients with multiple myeloma who received POMALYST 4 mg daily alone or in combination with dexamethasone, pomalidomide steady-state drug exposure was characterized by AUC(Τ) of 400 ng•h/mL and Cmax of 75 ng/mL. Following multiple doses, pomalidomide has an accumulation ratio of 27% to 31%.
Distribution
Pomalidomide has a mean apparent volume of distribution (Vd/F) between 62 and 138 L at steady state. Pomalidomide is distributed in semen of healthy subjects at a concentration of approximately 67% of plasma level at 4 hours postdose (~Tmax) after 4 days of once-daily dosing at 2 mg. Human plasma protein binding ranges from 12% to 44% and is not concentration dependent. Pomalidomide is a substrate for P-glycoprotein (P-gp).
Metabolism
Pomalidomide is primarily metabolized in the liver by CYP1A2 and CYP3A4. In vitro, CYP1A2 and CYP3A4 were identified as the primary enzymes involved in the CYP-mediated hydroxylation of pomalidomide, with additional minor contributions from CYP2C19 and CYP2D6.
Elimination
Pomalidomide is eliminated with a median plasma half-life of approximately 9.5 hours in healthy subjects and approximately 7.5 hours in patients with multiple myeloma. Pomalidomide has a mean total body clearance (CL/F) of 7-10 L/h.
Following a single oral administration of [14C]-pomalidomide (2 mg) to healthy subjects, approximately 73% and 15% of the radioactive dose was eliminated in urine and feces, respectively, with approximately 2% and 8% of the radiolabeled dose eliminated unchanged as pomalidomide in urine and feces.
Drug Interactions
Drugs that Inhibit Pomalidomide Metabolism
CYP1A2 Inhibitors: The effect of CYP1A2 inhibitors, in the absence of a co-administered CYP3A4 and P-gp inhibitor, is unknown. However, co-administration of fluvoxamine (a strong CYP1A2 inhibitor) in the presence of ketoconazole (a strong CYP3A4 and P-gp inhibitor) to 12 healthy male subjects increased exposure (geometric mean AUCINF) to pomalidomide by 146% compared to pomalidomide administered alone [see Dosage and Administration (2.2) and Drug Interactions (7.1)].
Strong CYP3A4 and P-glycoprotein (P-gp) Inhibitors: Co-administration of ketoconazole (a strong CYP3A4 and P-gp inhibitor) in 16 healthy male subjects resulted in an increased exposure (geometric mean AUCINF) to pomalidomide of 19% compared to pomalidomide administered alone.
Drugs that Induce Pomalidomide Metabolism
Strong CYP1A2 Inducers: Co-administration of POMALYST with drugs that are CYP1A2 inducers has not been studied and may reduce pomalidomide exposure.
Strong CYP3A4 Inducers: Co-administration of carbamazepine to 16 healthy male subjects decreased exposure (geometric mean AUCINF) to pomalidomide by 21% compared to pomalidomide administered alone.
Dexamethasone: Co-administration of multiple doses of 4 mg POMALYST with 20 mg to 40 mg dexamethasone (a weak to moderate inducer of CYP3A4) to patients with multiple myeloma had no effect on the pharmacokinetics of pomalidomide compared with pomalidomide administered alone.
In Vitro Inhibition of Drug Metabolizing Enzymes and Transporters by Pomalidomide
Pomalidomide does not inhibit or induce CYP450 enzymes or transporters in vitro.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies examining the carcinogenic potential of pomalidomide have not been conducted. One of 12 monkeys dosed with 1 mg/kg of pomalidomide (an exposure approximately 15-fold of the exposure in patients at the recommended dose of 4 mg/day) developed acute myeloid leukemia in a 9-month repeat-dose toxicology study.
Pomalidomide was not mutagenic or clastogenic in a battery of tests, including the bacteria reverse mutation assay (Ames test), the in vitro assay using human peripheral blood lymphocytes, and the micronucleus test in orally treated rats administered doses up to 2000 mg/kg/day.
In a fertility and early embryonic development study in rats, drug-treated males were mated with untreated or treated females. Pomalidomide was administered to males and females at doses of 25 to 1000 mg/kg/day. When treated males were mated with treated females, there was an increase in post-implantation loss and a decrease in mean number of viable embryos at all dose levels. There were no other effects on reproductive functions or the number of pregnancies. The lowest dose tested in animals resulted in an exposure (AUC) approximately 100-fold of the exposure in patients at the recommended dose of 4 mg/day. When treated males in this study were mated with untreated females, all uterine parameters were comparable to the controls. Based on these results, the observed effects were attributed to the treatment of females.
14 CLINICAL STUDIES
14.1 Multiple Myeloma
Trial 1 was a phase 2, multicenter, randomized open-label study in patients with relapsed multiple myeloma who were refractory to their last myeloma therapy and had received lenalidomide and bortezomib. Patients were considered relapsed if they had achieved at least stable disease for at least 1 cycle of treatment to at least 1 prior regimen and then developed progressive disease. Patients were considered refractory if they experienced disease progression on or within 60 days of their last therapy. A total of 221 patients were randomized to receive POMALYST alone or POMALYST with Low-dose Dex. In Trial 1, the safety and efficacy of POMALYST 4 mg, once daily for 21 of 28 days, until disease progression, were evaluated alone and in combination with Low-dose Dex (40 mg/day given only on Days 1, 8, 15, and 22 of each 28-day cycle for patients aged 75 years or younger, or 20 mg/day given only on Days 1, 8, 15, and 22 of each 28-day cycle for patients aged greater than 75 years). Patients in the POMALYST alone arm were allowed to add Low-dose Dex upon disease progression.
Table 4 summarizes the baseline patient and disease characteristics in Trial 1. The baseline demographics and disease characteristics were balanced and comparable between the study arms.
Table 4: Baseline Demographic and Disease-Related Characteristics – Trial 1 

POMALYST
  (n=108)
  POMALYST
+ Low-dose
Dex
  (n=113)
  Patient Characteristics
  Median age, years (range)   61 (37-88)   64 (34-88)
  Age distribution, n (%)
     <65 years
     ≥65 years
 
  65 (60.2)
  43 (39.8)
 
  60 (53.1)
  53 (46.9)
  Sex, n (%)
    Male
    Female

  57 (52.8)
  51 (47.2)

  62 (54.9)
  51 (45.1)
  Race/ethnicity, n (%)
    White
    Black or African American
    All other race
 
  86 (79.6)
  16 (14.8)
  6 (5.6)
 
  92 (81.4)
  17 (15)
  4 (3.6)
  ECOG Performance, n (%)
  Status 0-1
 
  95 (87.9)
 
  100 (88.5)
  Disease Characteristics
  Number of prior therapies
    Median, (min, max)
 
  5 (2, 12)
 
  5 (2, 13)
  Prior transplant, n (%)   82 (75.9)   84 (74.3)
  Refractory to bortezomib
  and lenalidomide, n (%)
  64 (59.3)   69 (61.1)

Data cutoff: 01 April 2011
Table 5 summarizes the analysis results of overall response rate (ORR) and duration of response (DOR), based on assessments by the Independent Review Adjudication Committee for the treatment arms in Trial 1. ORR did not differ based on type of prior antimyeloma therapy.
Table 5: Trial 1 Results 

POMALYST a
  (n=108)
  POMALYST +
  Low-dose Dex
  (n=113)
  Response
  Overall Response Rate
  (ORR),b n (%)
  8 (7.4)   33 (29.2)
  95% CI for ORR (%)   (3.3, 14.1)   (21.0, 38.5)
  Complete Response (CR), n (%)   0 (0.0)   1 (0.9)
  Partial Response (PR), n (%)   8 (7.4)   32 (28.3)
  Duration of Response (DOR)      
  Median, months   NE   7.4
  95% CI for DOR (months)   NE   (5.1, 9.2)
a Results are prior to the addition of dexamethasone.
b ORR = PR + CR per EBMT criteria.
CI, confidence interval; NE, not established (the median has not yet been reached).
Data cutoff: 01 April 2011
Trial 2 was a Phase 3 multi-center, randomized, open-label study, where POMALYST + Low-dose Dex therapy was compared to High-dose Dex in adult patients with relapsed and refractory multiple myeloma, who had received at least two prior treatment regimens, including lenalidomide and bortezomib, and demonstrated disease progression on or within 60 days of the last therapy. Patients with creatinine clearance ≥ 45mL/min qualified for the trial. A total of 455 patients were enrolled in the trial: 302 in the POMALYST + Low-dose Dex arm and 153 in the High-dose Dex arm. Patients in the POMALYST + Low-dose Dex arm were administered 4 mg POMALYST orally on Days 1 to 21 of each 28-day cycle. Dexamethasone (40 mg) was administered once per day on Days 1, 8, 15 and 22 of a 28-day cycle. Patients > 75 years of age started treatment with 20 mg dexamethasone using the same schedule. For the High-dose Dex arm, dexamethasone (40 mg) was administered once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle. Patients > 75 years of age started treatment with 20 mg dexamethasone using the same schedule. Treatment continued until patients had disease progression.
Baseline patient and disease characteristics were balanced and comparable between the study arms, as summarized in Table 6. Overall, 94% of patients had disease refractory to lenalidomide, 79% had disease refractory to bortezomib and 74% had disease refractory to both lenalidomide and bortezomib.
Table 6: Baseline Demographic and Disease-Related Characteristics – Trial 2 

POMALYST + Low-dose Dex
(N=302)
High-dose Dex
 
(N=153)
Patient Characteristics
Median Age, years (range) 64 (35, 84) 65 (35, 87)
Age Distribution n (%)
< 65 years
≥ 65 years
 
158 (52)
144 (48)
 
74 (48)
79 (52)
Sex n (%)
Male
Female
 
181 (60)
121 (40)
 
87 (57)
66 (43)
Race/Ethnicity n (%)
White
Black or African American
Asian
Other Race
Not Collected
 
244 (81)
4 (1)
4 (1)
2 (1)
48 (16)
 
113 (74)
3 (2)
0 (0)
2 (1)
35 (23)
ECOG Performance n (%)
Status 0
Status 1
Status 2
Status 3
Missing
 
110 (36)
138 (46)
52 (17)
0 (0)
2 (1)
 
36 (24)
86 (56)
25 (16)
3 (2)
3 (2)
Disease Characteristics
Number of Prior Therapies
Median, (Min, Max)
 
5 (2, 14)
 
5 (2, 17)
Prior stem cell transplant n (%) 214 (71) 105 (69)
Refractory to bortezomib and lenalidomide n (%) 225 (75) 113 (74)
Data cutoff: 01March 2013
Table 7 summarizes the progression free survival (PFS) and overall response rate (ORR) based on the assessment by the Independent Review Adjudication Committee (IRAC) review at the final PFS analysis and overall survival (OS) at the OS analysis. PFS was significantly longer with POMALYST + Low-dose Dex than High-dose Dex: HR 0.45 (95% CI: 0.35-0.59 p < 0.001). OS was also significantly longer with POMALYST + Low-dose Dex than High-dose Dex: HR 0.70 (95% CI: 0.54-0.92 p = 0.009).The Kaplan-Meier curves for PFS and OS for the ITT population are provided in Figures 1 and 2, respectively.
Table 7: Trial 2 Results

POMALYST + Low-dose Dex
(N=302)
High-dose Dex
 
(N=153)
Progression Free Survival Time
Number (%) of events 164 (54.3) 103 (67.3)
Mediana (2-sided 95% CI) (months) 3.6 [3.0, 4.6] 1.8 [1.6, 2.1]
Hazard Ratio (Pom+LD-Dex:HD-Dex) 2-Sided 95% CIb 0.45 [0.35, 0.59]
Log-Rank Test 2-sided P-Valuec <0.001
Overall Survival Timed
Number (%) of deaths 147 (48.7) 86 (56.2)
Mediana (2-sided 95% CI) (months) 12.4 [10.4, 15.3] 8.0[6.9, 9.0]
Hazard Ratio (Pom+LD-Dex:HD-Dex) 2-Sided 95% CIe 0.70 [0.54, 0.92]
Log-Rank Test 2-sided P-Value f, g 0.009
Overall Response Rate, n (%) 71 (23.5) 6 (3.9)
  Complete Response 1 (0.3) 0
  Very Good Partial Response 8 (2.6) 1 (0.7)
  Partial Response 62 (20.5) 5 (3.3)
Note: CI=Confidence interval; HD-Dex=High dose dexamethasone; IRAC=Independent Review Adjudication Committee; LD-Dex=Low dose dexamethasone.
a The median is based on Kaplan-Meier estimate.
b Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups, stratified by age (≤75 vs >75), diseases population (refractory to both Lenalidomide and Bortezomib vs not refractory to both drugs), and prior number of antimyeloma therapy (=2 vs >2), stratification factors for the trial.
c The p-value is based on a stratified log-rank test with the same stratification factors as the above Cox model.
d 53% of patients in the High-dose Dex arm subsequently received POMALYST.
e Based on Cox proportional hazards model (unstratified) comparing the hazard functions associated with treatment groups.
f The p-value is based on an unstratified log-rank test.
gAlpha control for PFS and OS.
Data cutoff: 07 Sep 2012 for PFS
Data cutoff: 01 Mar 2013 for OS and ORR
Figure 1: Progression Free Survival Based on IRAC Review of Response by IMWG Criteria (Stratified Log Rank Test) (ITT Population)


Data cut-off: 07 Sep 2012
Figure 2: Kaplan-Meier Curve of Overall Survival (ITT Population)


Data cutoff: 01 Mar 2013
15 REFERENCES
1. OSHA Hazardous Drugs. OSHA. [Accessed on 29 January 2013, from http://www.osha.gov/SLTC/hazardousdrugs/index.html]
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
Dark blue opaque cap and yellow opaque body, imprinted “POML” on the cap in white ink and “1 mg” on the body in black ink
  1 mg bottles of 21        (NDC 59572-501-21)
  1 mg bottles of 100      (NDC 59572-501-00)
Dark blue opaque cap and orange opaque body, imprinted “POML” on the cap and “2 mg” on the body in white ink
  2 mg bottles of 21        (NDC 59572-502-21)
  2 mg bottles of 100      (NDC 59572-502-00)
Dark blue opaque cap and green opaque body, imprinted “POML” on the cap and “3 mg” on the body in white ink
  3 mg bottles of 21        (NDC 59572-503-21)
  3 mg bottles of 100      (NDC 59572-503-00)
Dark blue opaque cap and blue opaque body, imprinted “POML” on the cap and “4 mg” on the body in white ink
  4 mg bottles of 21        (NDC 59572-504-21)
  4 mg bottles of 100      (NDC 59572-504-00)
16.2 Storage
Store at 20°C-25°C (68°F-77°F); excursions permitted to 15°C-30°C (59°F-86°F). [See USP Controlled Room Temperature].
16.3 Handling and DisposalCare should be exercised in handling of POMALYST. POMALYST capsules should not be opened or crushed. If powder from POMALYST contacts the skin, wash the skin immediately and thoroughly with soap and water. If POMALYST contacts the mucous membranes, flush thoroughly with water.


Pomalyst(pomalidomide,泊马度胺)获FDA核准治疗多发性骨髓瘤
新泽西州萨米特–(BUSINESS WIRE)–(美国商业资讯) — Celgene Corporation (NASDAQ: CELG)今天宣布,美国食品药品管理局(FDA)已核准品牌药物POMALYST®(泊马度胺)用于既往接受过至少2种药物(包括来那度胺和硼替佐米)且最近治疗进行中或治疗完成60天内疾病进展的多发性骨髓瘤患者。
核准的依据是缓解率。生存或症状改善等临床收益尚未得到验证。
该核准得到MM-002试验结果的支持,该试验为II期随机开放研究,评估泊马度胺(每28天周期的第1-21天4毫克每天一次)联合低剂量地塞米松(≤75岁的患者仅在每28天周期的第1、8、15和22天每天给药40毫克,>75岁的患者仅在每28天周期的第1、8、15和22天每天给药20毫克)vs泊马度胺(每28天周期的第1-21天4毫克每天一次)单药用于最近骨髓瘤治疗难治且已用过来那度胺和硼替佐米的复发性多发性骨髓瘤患者。
221例可评估缓解的患者中,获得部分缓解或更佳的患者,泊马度胺联合低剂量地塞米松组vs泊马度胺单药组分别为29.2% (95% CI 21.0, 38.5) vs 7.4% (95% CI 3.3, 14.1)。由独立评审裁定委员会(IRAC)按欧洲血液和骨髓移植组(EMBT)标准评定缓解,据此计算总缓解率。缓解的中位持续时间,泊马度胺联合低剂量地塞米松组为7.4个月(95% CI 5.1, 9.2),而泊马度胺单药组尚未达到中位持续时间。
POMALYST是沙利度胺的类似物,妊娠期禁用,仅通过一项名为POMALSYT REMSTM的限制性分销计划供药。接受POMALYST治疗的多发性骨髓瘤患者可发生深静脉血栓形成(DVT)和肺栓塞(PE)。请参阅完整的处方信息,包括黑框“警示”、“禁忌症”、“警示与注意事项”和“不良反应”。
该研究中,219例患者可评估安全性。泊马度胺联合低剂量地塞米松组vs泊马度胺单药组最常见的3度或4度不良反应(≥15%)分别为中性粒细胞减少(38%和47%)、贫血(21%和22%)、血小板减少(19%和22%)和肺炎(23%和16%)。
POMALYST在美国仅通过一项名为POMALSYT REMSTM的限制性分销计划供药。
POMALYST® 是Celgene Corporation的注册商标
关于POMALYST®
POMALYST®口服药含有IMiDs® 化合物泊马度胺。POMALYST和其他IMiDs化合物仍在一百多项临床试验中接受评估。
POMALYST®(泊马度胺)适用于既往接受过至少2种药物(包括来那度胺和硼替佐米)且最近治疗进行中或治疗完成60天内疾病进展的多发性骨髓瘤患者。核准的依据是缓解率。生存或症状改善等临床收益尚未得到验证。
重要安全性信息
警示:
胚胎-胎儿毒性和静脉血栓栓塞
胚胎-胎儿毒性
POMALYST妊娠期禁用。POMALYST是沙利度胺的类似物。已知沙利度胺可导致人类畸胎,可导致重度出生缺陷或胚胎-胎儿死亡。育龄女性在启用POMALYST治疗之前须经2次妊娠试验显示阴性。
育龄女性在POMALYST治疗期间及治疗停止4周内须使用2种避孕方法或坚持杜绝异性性交。
POMALYST仅通过一项名为POMALSYT REMSTM的限制性分销计划供药。
静脉血栓栓塞
接受POMALYST治疗的多发性骨髓瘤患者可发生深静脉血栓形成(DVT)和肺栓塞(PE)。临床试验中采取了预防性的抗血栓形成措施。可考虑预防性措施,事先必须评估个体患者的基础危险因素
禁忌症:
妊娠
POMALYST可引起胎儿损伤,禁用于妊娠女性。如果在妊娠期使用了该药,或患者在使用该药期间妊娠,患者必须了解胎儿可能面临的危害
泊马度胺是沙利度胺的类似物,大鼠和兔子试验均显示,在器官发生阶段给药,可引起畸胎。
警示与注意事项
胚胎-胎儿毒性
育龄女性:POMALYST治疗期间及治疗完成至少4周内必须避免妊娠。在启用POMALYST之前4周起、治疗期间、中断给药期间及POMALYST停药后至少4周内,必须坚持杜绝异性性交或使用2种可靠的避孕方法。在启用治疗之前须经2次妊娠试验显示阴性。
男性:泊马度胺用药患者的精液中可检出该药。POMALYST治疗期间及POMALYST停药后28天内,用药男性在与育龄女性的任何性交中必须始终使用乳胶或合成避孕套,即使该男性已成功结扎输精管。用药男性不得捐赠精液。
献血:POMALYST治疗期间及停药后1个月内,患者不得献血,因为该血液可能输给妊娠女性患者,而此类女性的胎儿不应暴露于POMALYST。
POMALYST REMS计划
由于胚胎-胎儿风险,POMALYST仅在风险评估和减少策略(REMS)下通过一项名为“POMALYST REMS”的限制性分销计划供药 。处方者和药剂师必须通过该计划的认证;患者必须签署一份协议表格并满足要求。有关POMALYST REMS计划的进一步信息,请访问[celgeneriskmanagement.com] 或拨打电话1-888-423-5436。
静脉血栓栓塞:
接受POMALYST的患者曾发生静脉血栓栓塞,并报告为严重不良反应。该试验要求所有患者均接受预防性治疗或抗血栓治疗。DVT或PE发生率为3%。可考虑抗凝预防性治疗,事先必须评估个体患者的基础危险因素。
血液学毒性:
50%的患者报告任何程度的中性粒细胞减少,中性粒细胞减少是最常报告的3/4度不良事件,其次是贫血和血小板减少。患者须监测血液学毒性,尤其是中性粒细胞减少,最初8周须每周检查一次全血细胞计数,然后每月一次。对于3度或4度血液学毒性,须根据临床和实验室结果继续治疗或调整治疗。处治中性粒细胞减少和血小板减少时,建议中断给药和/或调整剂量。
超敏反应:
各研究均剔除了既往史中有沙利度胺或来那度胺相关严重超敏反应的患者,这些患者发生超敏反应的风险较高。
头晕和意识模糊状态:18%的患者出现头晕,12%的患者出现意识模糊状态;1%的患者出现3/4度头晕,3%的患者出现3/4度意识模糊状态。告知患者回避头晕或意识模糊可能构成问题的场合,在没有充分医嘱时不要服用其他可能引起头晕或意识模糊的药物。
神经病变:
18%的患者发生神经病变(近9%为外周神经病变)。3度或更严重的神经病变不良反应病例未见报道。
第二种原发性恶性肿瘤的风险:POMALYST作为研究用药治疗多发性骨髓瘤以外的其他疾病时曾有报道发生急性粒细胞白血病。
不良反应
在219例接受POMALYST单药(107例)或POMALYST+低剂量地塞米松(低剂量地松)(112例)患者的临床试验中,所有患者均出现至少一次治疗中发生的不良反应。
POMALYST单药vs POMALYST +低剂量地塞米松组,常见不良反应(≥30%)分别包括疲乏和无力(55%, 63%)、中性粒细胞减少(52%, 47%)、贫血(38%, 39%)、便秘(36%, 35%)、恶心(36%,22%)、腹泻(34%, 33%)、呼吸困难(34%, 45%)、上呼吸道感染(32%, 25%)、背痛(32%, 30%)和发热(19%, 30%)
出现至少一次治疗中发生的NCI CTC 3度或4度不良反应的患者,POMALYST单药组为90%,POMALYST +低剂量地松组为88%
POMALYST单药vs POMALYST +低剂量地塞米松组,最常见的3/4度不良反应(≥15%)分别包括中性粒细胞减少(47%, 38%)、贫血(22%, 21%)、血小板减少(22%, 19%)和肺炎(16%, 23%)。若出现中性粒细胞减少和中性粒细胞减少以外的其他3度或4度毒性,则暂停治疗,待毒性消退至≤2度,由医生酌情重启治疗,剂量比前次剂量低1毫克出现至少一次治疗中发生的严重不良反应的患者,POMALYST单药组为67%,POMALYST +低剂量地松组为62%
POMALYST单药vs POMALYST +低剂量地塞米松组,最常见的严重不良反应(≥5%)分别包括肺炎(14%, 19%)、肾功能衰竭(8%, 6%)、呼吸困难(5%, 6%)、脓毒血症(6%, 3%)、发热(3%, 5%)、脱水(5%, 3%)、高钙血症(5%, 2%)、尿路感染(0%, 5%)和发热性中性粒细胞减少 (5%, 1%)
药物相互作用
POMALYST尚未正式开展过药物相互作用研究。泊马度胺主要由CYP1A2和CYP3A代谢。泊马度胺同时是P糖蛋白(P-gp)的底物。POMALYST应避免与强效抑制或诱导CYP1A2、CYP3A或 P-gp的药物合用。吸烟可降低CYP1A2诱导所致的泊马度胺暴露量 。应告知患者,吸烟可能降低泊马度胺的有效性。
特殊人群用药
妊娠:治疗期间如果妊娠,立即停药,将患者转诊至有生殖毒性经验的产科医生/妇科医生,接受进一步评估和咨询。任何疑似的POMALYST胎儿暴露须通过 MedWatch计划上报FDA,电话是1-800-332-1088,同时上报Celgene Corporation,电话是1-888-423-5436。
哺乳母亲:泊马度胺是否在人类乳汁中有分泌尚属未知。泊马度胺在哺乳期大鼠乳汁中有分泌。由于许多药物在人类乳汁中有分泌、且由于哺乳婴儿可能出现POMALYST所致的不良反应,在决定是否停止哺乳或停药时必须考虑该药对母亲的重要性。
儿科用药:
POMALYST在18岁以下患者中的安全性和有效性尚未确立。
老年用药:
POMALYST剂量无需按年龄调整。与≤65岁的患者相比,≥65岁的患者较易发生肺炎。
肝肾功能损害:泊马度胺通过肝脏代谢。泊马度胺及其代谢产物主要经肾脏排泄。肝肾功能损害对泊马度胺的安全性、有效性和药代动力学的影响尚未评估。血清肌酐>3.0毫克/分升的患者应避免使用POMALYST。血清胆红素>2.0毫克/分升且AST/ALT >正常值上限3.0倍的患者应避免使用POMALYST。
请参阅完整处方信息,包括黑框“警示”、“禁忌症”、“警示与注意事项”和“不良反应”。
POMALYST(泊马度胺)适用于既往接受过至少2种药物(包括来那度胺和硼替佐米)且最近治疗进行中或治疗完成60天内疾病进展的多发性骨髓瘤患者。核准的依据是缓解率。生存或症状改善等临床收益尚未得到验证。
关于多发性骨髓瘤
多发性骨髓瘤(又名骨髓瘤或浆细胞骨髓瘤)是一种血液癌症,表现为骨髓中恶性浆细胞增生。浆细胞属于白细胞,可帮助生成名为免疫球蛋白的抗体,以对抗感染和疾病。但多数多发性骨髓瘤患者中出现一些细胞,生成一种名为病变蛋白(又名M蛋白)的免疫球蛋白,对机体无益。此外,恶性浆细胞可替代正常浆细胞和其他对免疫系统至关重要的白细胞。多发性骨髓瘤细胞还能附着在骨骼等其他机体组织上形成肿瘤。该病的病因不明

责任编辑:admin


相关文章
POMALYST(POMALIDOMIDE)CAPSULE;ORAL
泊马度胺胶囊|Imnovid(pomalidomide Capsules)
Imnovid(pomalidomide Capsules,泊马度胺胶囊)
泊马度胺胶囊Imnovid(Pomalidomide)
美国FDA批准pomalidomide用于晚期多发性骨髓瘤的三线治疗
FDA批准多发性骨髓瘤新药(Pomalyst)泊马度胺
泊马度胺胶囊(Pomalyst Pomalidomide Capsules)
POMALYST(pomalidomide)Capsules
泊马度胺胶囊|POMALYST(pomalidomide)Capsules
泊马度胺胶囊Pomalyst(pomalidomide)
 

最新文章

更多

· TAGRISSO(osimertinib t...
· ZYKADIA(CERITINIB, LDK...
· YONDELIS(trabectedin f...
· Nasea OD Tablets(Ramo...
· DOXIL(doxorubicin hydr...
· KYTRIL Injection(盐酸...
· NEULASTA(非格司亭注射...
· KEYTRUDA(派姆单抗 pemb...
· ZOLINZA(VORINOSTAT)C...
· Zoladex(GOSERELIN ACE...

推荐文章

更多

· TAGRISSO(osimertinib t...
· ZYKADIA(CERITINIB, LDK...
· YONDELIS(trabectedin f...
· Nasea OD Tablets(Ramo...
· DOXIL(doxorubicin hydr...
· KYTRIL Injection(盐酸...
· NEULASTA(非格司亭注射...
· KEYTRUDA(派姆单抗 pemb...
· ZOLINZA(VORINOSTAT)C...
· Zoladex(GOSERELIN ACE...

热点文章

更多

· DOXIL(doxorubicin hydr...
· TAGRISSO(osimertinib t...
· Nasea OD Tablets(Ramo...
· KYTRIL Injection(盐酸...
· YONDELIS(trabectedin f...
· ZYKADIA(CERITINIB, LDK...